When a new cancer treatment is approved based on a clinical trial, the next step is seeing how it performs in the real world. New research presented at the ASCO 2026 Annual Meeting provides encouraging news for people with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer. The study found that mirvetuximab soravtansine (Elahere®) delivered similar […]
Platinum-resistant ovarian cancer remains one of the greatest challenges in ovarian cancer care. When ovarian cancer returns or progresses within six months of platinum-based chemotherapy, treatment options become more limited, and the disease is often harder to control. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers presented new data from the […]
A large phase III study called the CHIPRO trial, presented at the 2026 ASCO Annual Meeting, looked at whether adding a targeted therapy called chiauranib to standard weekly chemotherapy (paclitaxel) could help people with platinum-resistant or platinum-refractory ovarian cancer. These are cancers that have either stopped responding to platinum chemotherapy or returned after it, and […]
The Galleri test reduced stage IV cancer diagnoses by 26% in the third screening round of the NHS-Galleri trial Presented at the 2026 ASCO Annual Meeting, full results from the NHS-Galleri trial showed that Stage IV diagnoses fell by 22% in the second screening round and 26% in the third across 12 high-mortality cancers (including […]
At the 2026 ASCO Annual Meeting, researchers shared updated results from a clinical trial called PRESERVE-004/GOG-3081, which studied a new chemotherapy-free combination treatment for platinum-resistant ovarian cancer. This is a group of cancers that has stopped responding to standard chemotherapy, which often makes treatment more difficult. What the study tested The study looked at two […]
Patients with advanced ovarian cancer that comes back or keeps growing after platinum chemotherapy often have very few treatment options, and it has been hard to achieve long-lasting control of the disease. Early results presented at ASCO 2026 from a new experimental treatment called IMA203CD8 are showing encouraging signs that this may change for some […]
A new class of targeted therapy is showing striking results for one of oncology’s most difficult-to-treat populations. At ASCO 2026, results from the NAPISTAR 1-01 trial reported that the antibody drug conjugate (ADC) TUB-040 had a confirmed overall response rate (cORR) of 61% in patients with platinum-resistant ovarian cancer (PROC), a population where treatment options […]
For people living with platinum-resistant ovarian cancer, treatment options have expanded in recent years with the approval of mirvetuximab soravtansine (Elahere®), a targeted therapy designed for tumors that express high levels of folate receptor alpha (FRα). While the drug has shown encouraging effectiveness, many patients have questions about its side effects—particularly its effects on the […]
Cancer survivorship often comes with ongoing challenges, including sleep problems, fatigue, anxiety, and low mood. A study presented at the 2026 ASCO Annual Meeting adds strong evidence that a simple, structured yoga program may help ease many of these symptoms in a meaningful way. These findings are especially relevant for people living after ovarian and […]
Researchers presented intriguing findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, suggesting that a short period of fasting around chemotherapy treatments may help some patients with advanced ovarian cancer respond better to treatment. While the study was small and more research is needed, the results have generated excitement because fasting is […]
